Hasil Telusur
OMACETAXINE MEPESUCCINATE SHOWS ACTIVITY IN ...
MarketWatch (press release) - 1 Jun 2012
Pooled Safety Analysis of Omacetaxine Mepesuccinate in Patients With Chronic Myeloid Leukemia (CML) Resistant to Tyrosine-Kinase Inhibitors (TKIs).
Kinase Inhibitor Trials Show Melanoma Benefits
Drug Discovery & Development - 7 Jun 2012
GlaxoSmithKline has release data from two Phase 3 studies evaluating single-agent therapy with dabrafenib and trametinib in patients with metastatic ...
Astex Pharmaceuticals Earns $5.4 Million Milestone on Phase I Trial ...
MarketWatch (press release) - 13 Jun 2012
Astex Pharmaceuticals Earns $5.4 Million Milestone on Phase I Trial Initiation of a FGFR Kinase Inhibitor. DUBLIN, Calif., Jun 13, 2012 (GlobeNewswire via ...
Astex Pharmaceuticals Earns $5.4 Million Milestone on Phase I Trial ...
GlobeNewsWire (press release) - 13 Jun 2012
Astex Pharmaceuticals Earns $5.4 Million Milestone on Phase I Trial Initiation of a FGFR Kinase Inhibitor. DUBLIN, Calif., June 13, 2012 (GLOBE NEWSWIRE) ...
Astex lands £3.5m milestone as cancer drug enters Phase I Cabume - Cambridge technology news
Seluruh 19 artikel berita »
Cell Therapeutics Completes Acquisition of Pacritinib a Highly ...
MarketWatch (press release) - 3 Jun 2012
About PacritinibPacritinib is an oral, once a day, tyrosine kinase inhibitor (TKI) with dual activity against JAK2 and FMS-like tyrosine kinase 3 ("FLT3"). Mutations ...
Cell Therapeutics Says It Completes Acquisition Of Pacritinib - Quick ... NASDAQ
Seluruh 16 artikel berita »
Inhibition of Src kinase activity attenuates amyloid associated ...
7thSpace Interactive (press release) - 6 Jun 2012
Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease - up-to-the-minute news and headlines.
Patients with NK/T-cell lymphomas might benefit from treatment with ...
News-Medical.net - 15 Jun 2012
Patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor according to a study published in Cancer Discovery, a journal of the ...
MethylGene Presents MGCD265 Data at the 2012 American Society ...
MarketWatch (press release) - 4 Jun 2012
The poster, entitled "MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation Phase I study" (Abstract #3039) ...
Xcovery Presents Phase 1 Clinical Results at ASCO Annual Meeting Marketwire (press release)
MethylGene (MYG-TO, MYLGF-OTC): Initiating with an Outperform Zacks.com
Seluruh 10 artikel berita »
Constitutively active c-Met kinase in PC-3 cells is autocrine ...
7thSpace Interactive (press release) - 28 Mei 2012
In the current study we examined the response of PC-3 cells to an anti-HGF neutralizing antibody or a small molecule Met kinase inhibitor (BMS-777607).
Xcovery Presents Phase 1 Clinical Results at ASCO Annual Meeting
MarketWatch (press release) - 4 Jun 2012
VEGFR tyrosine kinase inhibitors have characteristically demonstrated benefit in a variety of cancers, though it has been well documented that the dosage and ...
Tidak ada komentar:
Posting Komentar
Silahkan Komentar jangan lupa sertakan alamatmu.